Serum NfL and GFAP Biomarkers in 204 Post-COVID Syndrome Patients and Controls

Featuring serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) biomarker measurements from a prospective case-control study of 102 Post-COVID syndrome (PCS) patients and 102 recovered controls. The data was analyzed to investigate evidence of CNS injury after adjusting for confounders like age, sex, and renal function (eGFR).

Use Cases

• Analyze the correlation between eGFR and serum NfL (ρ = -0.23) or GFAP (ρ = -0.33) concentrations to understand renal function's influence on biomarkers.
• Compare adjusted GFAP levels between PCS patients and recovered controls to identify subtle astroglial signals, as shown in the age- and sex-matched cohort analysis (β = 0.15, p = 0.025).
• Build a multivariable linear regression model using log-transformed NfL and GFAP, adjusted for age, sex, and eGFR, to test for independent group differences.
• Examine the primary determinant role of age on NfL and GFAP concentrations across the 204-subject cohort.

Strengths

• Includes biomarker data from 204 total subjects (102 PCS patients and 102 recovered controls), providing a matched case-control structure.
• Biomarkers were quantified using the Simoa® (Quanterix) platform, a sensitive method for protein detection.
• Analysis includes rigorous statistical adjustment for key confounders: age, sex, and eGFR, as detailed in the methods.

Limitations

• The dataset is small at 40.3 KB, suggesting limited raw data or a summary document rather than a full tabular dataset.
• Specific column names, sample data, and row counts for individual measurements are unknown from the provided input.
• The study is a single-center design, which may limit the generalizability of the findings.

Provenance

Source

figshare, authored by Michael Wunderle.

Collection Method

Prospective single-center case–control study with serum biomarker quantification using Simoa®.

Freshness

Last updated on 2026-03-20.